Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.